Table S1. Patient clinical characteristics by type of immune checkpoint inhibitor therapy. Table S2. Short-term outcomes by grade of lipase elevation for patients who received steroids. Table S3. Short-term outcomes by the grade of lipase elevation for patients who received intravenous fluids. Table S4. Multivariable Cox regression for overall survival. (DOCX 16 kb
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure ...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...
Figure S4. Kaplan-Meier overall survival curves in patients who did and did not have long-term adver...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Figure S5. Kaplan-Meier overall survival curves in patients who did and did not receive steroids for...
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
Figure S6. Kaplan-Meier overall survival curves in patients who did and did not have symptoms of pan...
Figure S3. Kaplan-Meier overall survival curves in patients who resumed and discontinued immune chec...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
Figure S1. Computed tomography findings of ICIPI. (A) Images from a patient with pancreatic metastas...
Table S1. Descriptive statistics for total cohort and three subgroups stratified by each institution...
Additional file 1: Table S1. Baseline laboratory values of patients in ASCVD events study before and...
Table S1. Common Terminology Criteria of Adverse Events v5.0 grading for diarrhea and colitis. Table...
Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure ...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...
Figure S4. Kaplan-Meier overall survival curves in patients who did and did not have long-term adver...
Figure S2B. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by t...
Figure S5. Kaplan-Meier overall survival curves in patients who did and did not receive steroids for...
Figure S2A. Long-term adverse outcomes of immune checkpoint inhibitor-induced pancreatic injury by c...
Figure S6. Kaplan-Meier overall survival curves in patients who did and did not have symptoms of pan...
Figure S3. Kaplan-Meier overall survival curves in patients who resumed and discontinued immune chec...
Table S1. Characteristics of patients by typicality of cholecystitis symptoms. Table S2. Characteris...
Figure S1. Computed tomography findings of ICIPI. (A) Images from a patient with pancreatic metastas...
Table S1. Descriptive statistics for total cohort and three subgroups stratified by each institution...
Additional file 1: Table S1. Baseline laboratory values of patients in ASCVD events study before and...
Table S1. Common Terminology Criteria of Adverse Events v5.0 grading for diarrhea and colitis. Table...
Figures S5 to S7 Global immune-related adverse events (irAEs) with ipilimumab all dosage, 3 mg/kg, a...
Comparison of prognostic factors according to the numbers of peptide-specific responses (n = 36 HLA-...
Table S1. Effect of steroid treatment duration and timing to SIT initiation after IMC onset. Figure ...
Table S1. Immune Checkpoint Inhibitors (CPIs) in Patients with Cancer and Prior Solid Organ Transpla...